A Multicenter, Randomized, Placebo-controlled, Parallel-arm Study to Investigate the Efficacy, Pharmacokinetics, and Safety of CSL312 in Subjects With Hereditary Angioedema
Phase of Trial: Phase II
Latest Information Update: 08 Feb 2019
At a glance
- Drugs CSL 312 (Primary) ; CSL 312 (Primary)
- Indications Hereditary angioedema
- Focus Therapeutic Use
- Sponsors CSL Behring
- 07 Jan 2019 Planned End Date changed from 1 Nov 2020 to 1 Sep 2020.
- 07 Jan 2019 Planned primary completion date changed from 1 Jan 2020 to 1 Aug 2019.
- 06 Nov 2018 Status changed from not yet recruiting to recruiting.